Ralf Otto Named COO at Rentschler Biopharma
Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.
Rentschler Biopharma, a contract development and manufacturing organization for biopharmaceuticals, appointed Ralf Otto as chief operating officer (COO), effective Feb. 1, 2018, succeeding Thomas Siklosi, who will move to Dr. Rentschler Holding GmbH & Co. KG, according to a Jan. 31, 2018 press statement.
Otto-who will be responsible for development, manufacturing, and quality management-has more than 20 years at senior positions in industry and management consulting and has overseen all stages of the biopharmaceutical value chain.
Most recently, he was a Partner at McKinsey & Company. Previously, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim and as vice-president Biopharma Operations, Otto headed the Boehringer site in Fremont, CA.
Source: Rentschler Biopharma SE
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
